ABSTRACT
COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.
Subject(s)
COVID-19 , Radiation Injuries , Humans , SARS-CoV-2ABSTRACT
A novel coronavirus pneumonia (COVID-19) epidemic in a geracomium was retrospectively investigated and analyzed. The "novel coronavirus pneumonia prevention and control scheme (Third edition)" recommended questionnaire and the "novel coronavirus pneumonia epidemiological survey guide (Trial first edition)" were adopted. The novel coronavirus pneumonia was found in 8 nursing staff and the elderly in the geracomium. The median age was 59 years old, with a male/female ratio of 1:7. It was diagnosed 4-15 days after the last exposure. 225 close contacts were identified, without three generations of continuous transmission. The possibility of asymptomatic infection is not excluded also;and one case died. The infection in this clustering was caused by confirmed case of COVID-19. It is suggested that prevention and control strategies should focus on the control and monitoring of geracomium, regulatory departments and other key places and key population.